Birchview Capital, LP Acadia Pharmaceuticals Inc Transaction History
Birchview Capital, LP
- $111 Million
- Q1 2025
A detailed history of Birchview Capital, LP transactions in Acadia Pharmaceuticals Inc stock. As of the latest transaction made, Birchview Capital, LP holds 263,400 shares of ACAD stock, worth $6.48 Million. This represents 3.94% of its overall portfolio holdings.
Number of Shares
263,400
Previous 338,400
22.16%
Holding current value
$6.48 Million
Previous $6.21 Million
29.54%
% of portfolio
3.94%
Previous 5.3%
Shares
17 transactions
Others Institutions Holding ACAD
# of Institutions
355Shares Held
163MCall Options Held
1.77MPut Options Held
307K-
Baker Bros. Advisors LP New York, NY42.9MShares$1.05 Billion8.49% of portfolio
-
Vanguard Group Inc Valley Forge, PA15.2MShares$374 Million0.0% of portfolio
-
Black Rock Inc. New York, NY12.1MShares$297 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY8.54MShares$210 Million2.32% of portfolio
-
State Street Corp Boston, MA6.99MShares$172 Million0.0% of portfolio
About ACADIA PHARMACEUTICALS INC
- Ticker ACAD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 161,843,008
- Market Cap $3.98B
- Description
- ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...